

01/10/00
J377 U.S. PTO

|-11-00

Docket Number 4-31157A/USN

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL402022937US
Express Mail Label Number

January 10, 2000
Date of Deposit

A
Box Seg

Address to: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) is the utility patent application of
Applicant (or identifier): Mary Ellen Digan, Philip Lake and Richard M. Wright
Title: ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES
THEREFOR

JC678 U.S. PTO
09/480236
01/10/00
Barcode

Enclosed are:

1. Specification (Including Claims and Abstract) - 115 pages
2. Drawings - 23 sheets
3. Unexecuted Declaration and Power of Attorney (original or copy)
4. Microfiche Computer Program (appendix)
5. Nucleotide and/or Amino Acid Sequence Submission
 Computer Readable Copy
 Paper Copy
 Statement Verifying Identity of Above Copies
6. Preliminary Amendment
7. Assignment Papers (Cover Sheet & Document(s))
8. English Translation of
9. Information Disclosure Statement
10. Certified Copy of Priority Document(s)
11. Return Receipt Postcard
12. Other:

Filing fee calculation:

- Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
 Before calculating the filing fee, please cancel claims

Basic Filing Fee								\$ 690	
Multiple Dependent Claim Fee (\$ 260)								\$	
Foreign Language Surcharge (\$ 130)								\$	
For	Number Filed		Number Extra			Rate			
Extra Claims	Total Claims	29	-20	9	x \$ 18	=	\$ 162		
	Independent Claims	2	-3	0	x \$ 78	=	\$		
					TOTAL FILING FEE		\$ 852		

- Please charge Deposit Account No. 19-0134 in the name of Novartis Pharmaceuticals Corporation in the amount of \$852. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Respectfully submitted,


Diane Furman Jan. 10, 2000
Diane E. Furman
Attorney for Applicants
Reg. No. 31,104
Tel. No. (908) 522-6924

Date: January 10, 2000